On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and is responsible for formulating the clinical strategy and direct clinical development of our Group.

On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company's BD affairs.

On February 22, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that National Medical Products Administration (NMPA) approved Phase Ib/II clinical trial application of the first domestic SIRPα-Fc fusion protein drug candidate targeting human CD47 (IMM01) combined with PD-1 antibody for the treatment of relapsed/ refractory malignant tumors.

February 15, 2022, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco", the company) announced that the first bispecific antibody-receptor recombinant protein (project number: IMM2902) targeting human CD47 x HER2 has completed the first patient enrollment and dosing, and administration process was smooth and successful.

On November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADCC-enhanced CTLA-4 antibody was approved by NMPA for clinical trial research. This is another major milestone for ImmueOnco.